Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial

BACKGROUND: Delayed-release oral mesalamine 2.4 g/day to 4.8 g/day has been shown to be effective in treating mildly to moderately active ulcerative colitis (UC), but it is unknown whether an initial dose of 4.8 g/day is more effective than 2.4 g/day in patients with mildly to moderately active UC a...

Full description

Bibliographic Details
Main Authors:	Stephen B Hanauer, William J Sandborn, Christian Dallaire, André Archambault, Bruce Yacyshyn, Chyon Yeh, Nancy Smith-Hall
Format:	Article
Language:	English
Published:	Hindawi Limited 2007-01-01
Series:	Canadian Journal of Gastroenterology
Online Access:	http://dx.doi.org/10.1155/2007/862917

id	doaj-ad3278ef9a5649a2863d0e867761ade8
record_format	Article
spelling	doaj-ad3278ef9a5649a2863d0e867761ade82020-11-25T00:37:00ZengHindawi LimitedCanadian Journal of Gastroenterology0835-79002007-01-01211282783410.1155/2007/862917Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I TrialStephen B Hanauer0William J Sandborn1Christian Dallaire2André Archambault3Bruce Yacyshyn4Chyon Yeh5Nancy Smith-Hall6University of Chicago School of Medicine, Chicago, Illinois, USADivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USAUniversité Laval, Québec, CanadaUniversité de Montréal, Montréal, Québec, CanadaProcter & Gamble Pharmaceuticals, Mason, Ohio, USAProcter & Gamble Pharmaceuticals, Mason, Ohio, USAProcter & Gamble Pharmaceuticals, Mason, Ohio, USABACKGROUND: Delayed-release oral mesalamine 2.4 g/day to 4.8 g/day has been shown to be effective in treating mildly to moderately active ulcerative colitis (UC), but it is unknown whether an initial dose of 4.8 g/day is more effective than 2.4 g/day in patients with mildly to moderately active UC and in the subgroup with moderate disease.http://dx.doi.org/10.1155/2007/862917
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Stephen B Hanauer William J Sandborn Christian Dallaire André Archambault Bruce Yacyshyn Chyon Yeh Nancy Smith-Hall
spellingShingle	Stephen B Hanauer William J Sandborn Christian Dallaire André Archambault Bruce Yacyshyn Chyon Yeh Nancy Smith-Hall Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial Canadian Journal of Gastroenterology
author_facet	Stephen B Hanauer William J Sandborn Christian Dallaire André Archambault Bruce Yacyshyn Chyon Yeh Nancy Smith-Hall
author_sort	Stephen B Hanauer
title	Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial
title_short	Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial
title_full	Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial
title_fullStr	Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial
title_full_unstemmed	Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial
title_sort	delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ascend i trial
publisher	Hindawi Limited
series	Canadian Journal of Gastroenterology
issn	0835-7900
publishDate	2007-01-01
description	BACKGROUND: Delayed-release oral mesalamine 2.4 g/day to 4.8 g/day has been shown to be effective in treating mildly to moderately active ulcerative colitis (UC), but it is unknown whether an initial dose of 4.8 g/day is more effective than 2.4 g/day in patients with mildly to moderately active UC and in the subgroup with moderate disease.
url	http://dx.doi.org/10.1155/2007/862917
work_keys_str_mv	AT stephenbhanauer delayedreleaseoralmesalamine48gday800mgtabletscomparedwith24gday400mgtabletsforthetreatmentofmildlytomoderatelyactiveulcerativecolitistheascenditrial AT williamjsandborn delayedreleaseoralmesalamine48gday800mgtabletscomparedwith24gday400mgtabletsforthetreatmentofmildlytomoderatelyactiveulcerativecolitistheascenditrial AT christiandallaire delayedreleaseoralmesalamine48gday800mgtabletscomparedwith24gday400mgtabletsforthetreatmentofmildlytomoderatelyactiveulcerativecolitistheascenditrial AT andrearchambault delayedreleaseoralmesalamine48gday800mgtabletscomparedwith24gday400mgtabletsforthetreatmentofmildlytomoderatelyactiveulcerativecolitistheascenditrial AT bruceyacyshyn delayedreleaseoralmesalamine48gday800mgtabletscomparedwith24gday400mgtabletsforthetreatmentofmildlytomoderatelyactiveulcerativecolitistheascenditrial AT chyonyeh delayedreleaseoralmesalamine48gday800mgtabletscomparedwith24gday400mgtabletsforthetreatmentofmildlytomoderatelyactiveulcerativecolitistheascenditrial AT nancysmithhall delayedreleaseoralmesalamine48gday800mgtabletscomparedwith24gday400mgtabletsforthetreatmentofmildlytomoderatelyactiveulcerativecolitistheascenditrial
_version_	1725302999885021184

Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial

Similar Items